Prasugrel
Medication used to prevent formation of blood clots / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Prasugrel?
Summarize this article for a 10 year old
Prasugrel, sold under the brand name Effient in the US, Australia and India, and Efient in the EU) is a medication used to prevent formation of blood clots. It is a platelet inhibitor and an irreversible antagonist of P2Y12 ADP receptors and is of the thienopyridine drug class. It was developed by Daiichi Sankyo Co. and produced by Ube and marketed in the United States in cooperation with Eli Lilly and Company.
Clinical data | |
---|---|
Trade names | Effient, Efient |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609027 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ≥79% |
Protein binding | Active metabolite: ~98% |
Elimination half-life | ~7 h (range 2 h to 15 h) |
Excretion | Urine (~68% inactive metabolites); feces (27% inactive metabolites) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.228.719 |
Chemical and physical data | |
Formula | C20H20FNO3S |
Molar mass | 373.44 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Prasugrel was approved for use in the European Union in February 2009,[1] and in the US in July 2009, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).[2]